Provider Briefing: Ciprofloxacin/Dexamethasone Availability in 2026

Ciprofloxacin/Dexamethasone 0.3%/0.1% otic suspension — marketed as Ciprodex by Alcon and now available in generic form — remains a first-line treatment for acute otitis externa and acute otitis media in pediatric patients with tympanostomy tubes. While the overall supply picture has improved since the generic launch in 2023, providers should be aware of the ongoing availability dynamics that continue to affect patient access.

This briefing covers the current shortage status, prescribing implications, cost and access considerations, and tools to help your patients locate this medication.

Timeline: How We Got Here

Understanding the supply history helps contextualize current availability:

• Pre-2023: Ciprodex was available only as a brand-name product from Alcon. As one of the most prescribed otic medications in the U.S., supply was generally stable but expensive, with cash prices exceeding $300 per bottle.
• March 2023: Dr. Reddy's Laboratories launched the first generic Ciprofloxacin/Dexamethasone 0.3%/0.1% otic suspension, significantly expanding the supply chain and introducing price competition.
• 2023–2024: Additional generic manufacturers, including Upsher-Smith, entered the market. Supply improved, though seasonal demand during summer months continued to create periodic spot shortages at the retail pharmacy level.
• 2025–2026: The medication is not listed on the FDA drug shortage database. However, localized availability gaps persist, particularly in high-demand periods and in areas with limited pharmacy infrastructure.

Prescribing Implications

The availability landscape has several implications for clinical practice:

Generic Substitution Is Routine

Generic Ciprofloxacin/Dexamethasone is therapeutically equivalent to brand-name Ciprodex (FDA AB-rated). Most pharmacies will automatically substitute the generic unless the prescriber writes "brand medically necessary." Given the significant price difference — $65–$145 for generic vs. $260–$350 for brand — generic substitution benefits most patients.

Consider Alternatives for Cost-Sensitive Patients

For patients with significant cost barriers, consider the clinical appropriateness of alternatives:

• Ofloxacin 0.3% otic solution: FDA-approved for otitis externa, otitis media with tympanostomy tubes, and chronic suppurative otitis media. Available generically at $15–$30. Lacks the anti-inflammatory component but is safe for perforated eardrums.
• Neomycin/Polymyxin B/Hydrocortisone (Cortisporin Otic): Effective for otitis externa with intact tympanic membranes. Generic pricing $20–$50. Contraindicated with perforated eardrums due to neomycin ototoxicity risk.

For a detailed clinical comparison, see our alternatives guide.

Prescribe by Generic Name When Possible

Writing prescriptions for "Ciprofloxacin/Dexamethasone 0.3%/0.1% otic suspension" rather than "Ciprodex" gives pharmacies maximum flexibility to dispense whichever version they have in stock, whether brand or generic from any manufacturer.

Current Availability Picture

As of early 2026, the availability situation is as follows:

• FDA shortage status: Not listed as a current shortage
• Brand (Ciprodex): Generally available through standard distribution channels, though some pharmacies may not stock it due to cost
• Generic: Available from multiple manufacturers (Dr. Reddy's, Upsher-Smith) through major distributors
• Spot shortages: Still reported at individual pharmacies, particularly during summer months (May–September) when otitis externa incidence peaks
• Geographic variation: Rural and underserved areas may have more limited access to both brand and generic versions

Cost and Access Considerations

Cost remains a significant barrier for uninsured and underinsured patients:

• Brand Ciprodex cash price: $260–$350 per 7.5 mL bottle
• Generic cash price: $65–$145 per 7.5 mL bottle
• Insurance coverage: Approximately 99% of commercial plans cover Ciprofloxacin/Dexamethasone. Typical copays: $10–$68
• Alcon copay card: Reduces brand-name cost to as low as $30 for commercially insured patients (not valid with government insurance)
• Discount programs: GoodRx and SingleCare coupons can reduce generic cost to approximately $65

For patients with financial hardship, the Alcon Patient Access Program and resources through NeedyMeds and RxAssist may provide additional support.

Tools and Resources for Your Practice

Several tools can help streamline the process of getting patients their medication:

Medfinder for Providers

Medfinder allows providers and care teams to check real-time pharmacy availability for Ciprofloxacin/Dexamethasone. Rather than having patients call pharmacy after pharmacy, you can direct them to medfinder.com/providers or check availability during the visit to identify pharmacies with current stock.

Patient Education Resources

Direct patients to these resources to help them navigate availability and cost:

• How to find Ciprofloxacin/Dexamethasone in stock near you
• How to save money on Ciprofloxacin/Dexamethasone
• Side effects: what to expect and when to call

Looking Ahead

The overall outlook for Ciprofloxacin/Dexamethasone availability is positive. With multiple generic manufacturers in the market and no formal FDA shortage listing, the supply chain is more resilient than it has been in years. However, seasonal demand patterns and the inherent limitations of pharmacy stocking for specialty otic products mean that individual patients will continue to encounter availability gaps.

Proactive measures — prescribing by generic name, discussing alternatives preemptively, and directing patients to availability tools like Medfinder — can help reduce the burden on patients and minimize treatment delays.

Final Thoughts

Ciprofloxacin/Dexamethasone remains an important part of the otic infection treatment toolkit. While true shortages are not the norm in 2026, helping patients navigate availability and cost continues to be a practical challenge. By staying informed about the current landscape and leveraging available tools, providers can help ensure patients get timely, effective treatment.

For a step-by-step workflow on helping patients find this medication, see our companion guide: How to help your patients find Ciprofloxacin/Dexamethasone in stock.